	US-Australian drug discovery company, Novogen Limited announced it has engaged Novotech, based in Australia, as its CRO to conduct its Phase I clinical study for the drug candidate, Cantrixil, which will commence in 2016. The Cantrixil Phase I study will be weighted towards ovarian cancer patients with the selection of a gynecological oncology site. However, patients with other cancer types will  also be eligible to enroll in this first study since early preclinical data suggests the drug candidate may benefit patients with a range of cancer types.
	 

Oncology

The Cantrixil Phase I study will be weighted towards ovarian cancer patients with the selection of a gynecological oncology site.